Race Oncology’s RC220 trial gets green light

1 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Race Oncology Ltd chair Peter Smith talked with Proactive about the approval the company has received from the Bellberry Human Research Ethics Committee (HREC). The approval allows the company to move forward with its clinical trial for RC220, a new formulation of bisantrene.

Smith explained that the trial aims to establish the safety of RC220 both as a standalone treatment and in combination with doxorubicin, a commonly used chemotherapy drug. "What we’ll be seeking to achieve is establishing the maximum tolerated dose for the combination of the two drugs together," he said.

The study will also investigate whether RC220 can reduce doxorubicin’s known toxicity to the cardiovascular system. Smith highlighted that doxorubicin can cause permanent heart damage, potentially reducing patient lifespan by the equivalent of a decade. The company aims to demonstrate that RC220 can enhance anti-cancer effects while mitigating heart-related side effects.

The trial will be conducted in multiple phases, beginning in Australia, with expansion planned into Korea and Hong Kong later in the year. Smith noted that the Cancer Care Foundation is playing a role in patient support and accessibility.

For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for future updates.

#RaceOncology #CancerResearch #ClinicalTrial #Biotech #Oncology #RC220 #Doxorubicin #CardioProtection #Pharma #MedicalResearch #CancerTreatment
Category
Oncology
Be the first to comment

Up Next